242,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
121 °P sammeln
  • Gebundenes Buch

This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. The management of patients with high-grade gliomas has historically been one of the most challenging and disheartening fields in medicine, where failure is the rule and longevity is the exception. The jaded often state that despite purported advances in surgical and radiotherapeutic techniques and a myriad of clinical trials of medical therapies, the s- vival statistics for glioblastoma have not changed in the last three decades. The nihilism associated with these tumors is such that…mehr

Produktbeschreibung
This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. The management of patients with high-grade gliomas has historically been one of the most challenging and disheartening fields in medicine, where failure is the rule and longevity is the exception. The jaded often state that despite purported advances in surgical and radiotherapeutic techniques and a myriad of clinical trials of medical therapies, the s- vival statistics for glioblastoma have not changed in the last three decades. The nihilism associated with these tumors is such that some practitioners still advise against treatment or even biopsy, recommending palliative care with the diagnosis based only on history and an MRI scan. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject. The fact is that we have recently entered an era where real progress is being made in our understanding and treatment of high-grade gliomas that is directly benefiting some patients. We are slowly but surely chipping away at this problem. One approach has exploited correlations between particular molecular markers and therapeutic response. The first such "breakthrough" in high-grade glioma was the observation that loss of chromosomes 1p and 19q uniformly predict chemosensitivity in anaplastic oligodendrogliomas (1).
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Rezensionen
From the reviews:

"...essential reading for many research scientists and students, as well as clinicans from multiple disciplines, including neurosurgeons, neurologists, medical neurooncologists, and radioation oncologists." -Journal of Neurosurgery

"This multi-author book edited by Gene Barnett from the Cleveland Clinic Foundation is a further title in the renowned series Current Clinical Oncology. Every chapter is written by experts in their field. ... It is primarily of interest to physicians who are involved with these tumor patients. ... the book may be of help for expertises in clinical forensic medicine by covering nearly all aspects of high-grade gliomas and providing the latest advances in diagnosis and therapy." (Andreas Büttner, Forensic Science, Medicine and Pathology, Issue 3, 2007)

"This is a good book if you are interested in high-grade gliomas, as many of us are who practice at cancer hospitals. ... If you have not yet heard of intracavitary chemotherapy wafers, brachy-therapy, convection therapy, nonconformal stereotactic radiotherapy devices, and all of the new chemotherapy agents, you will someday soon, and this is a good place to find that information. Each chapter is clearly written with a consistent style ... . The book is a recommended addition to the neuroradiologist's reference library." (American Journal of Neuroradiology, Vol. 28, September, 2007)

"Leaders in the field provide the latest information on the diagnosis and management of high-grade gliomas in this new groundbreaking text. ... Forefront areas of the clinical investigation are also covered with the promise of leading us to the treatments of tomorrow. ... All physicians treating brain tumors including neurosurgeons, neurologists and radiation oncologists will benefit from the coverage herein of the meaningful advances in our understanding of the biology of the high-grade gliomas that are now leading to better, more rational,patient-specific treatments." (Tumori, Vol. 93, 2007)

…mehr